These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 29346673)

  • 1. Commentary on "The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis".
    McGuire P; Englund A; Bhattacharyya S
    Schizophr Bull; 2018 Jan; 44(1):18-19. PubMed ID: 29346673
    [No Abstract]   [Full Text] [Related]  

  • 2. Cannabinoids and psychotic symptoms: A potential role for a genetic variant in the P2X purinoceptor 7 (P2RX7) gene.
    Boks MP; He Y; Schubart CD; Gastel WV; Elkrief L; Huguet G; Eijk KV; Vinkers CH; Kahn RS; Paus T; Conrod P; Hol EM; de Witte LD
    Brain Behav Immun; 2020 Aug; 88():573-581. PubMed ID: 32330591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabinoids and Schizophrenia: Risks and Therapeutic Potential.
    Manseau MW; Goff DC
    Neurotherapeutics; 2015 Oct; 12(4):816-24. PubMed ID: 26311150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.
    Hahn B
    Schizophr Bull; 2018 Jan; 44(1):46-53. PubMed ID: 29083450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabis with high cannabidiol content is associated with fewer psychotic experiences.
    Schubart CD; Sommer IE; van Gastel WA; Goetgebuer RL; Kahn RS; Boks MP
    Schizophr Res; 2011 Aug; 130(1-3):216-21. PubMed ID: 21592732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabidiol (CBD) as a novel treatment in the early phases of psychosis.
    Chesney E; Oliver D; McGuire P
    Psychopharmacology (Berl); 2022 May; 239(5):1179-1190. PubMed ID: 34255100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabinoids and psychosis.
    Sewell RA; Ranganathan M; D'Souza DC
    Int Rev Psychiatry; 2009 Apr; 21(2):152-62. PubMed ID: 19367509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects.
    van Amsterdam J; Brunt T; van den Brink W
    J Psychopharmacol; 2015 Mar; 29(3):254-63. PubMed ID: 25586398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabidiol as a potential treatment for psychosis.
    Schubart CD; Sommer IE; Fusar-Poli P; de Witte L; Kahn RS; Boks MP
    Eur Neuropsychopharmacol; 2014 Jan; 24(1):51-64. PubMed ID: 24309088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathways to psychosis in cannabis abuse.
    Shrivastava A; Johnston M; Terpstra K; Bureau Y
    Clin Schizophr Relat Psychoses; 2015 Apr; 9(1):30-5. PubMed ID: 23491968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of drug use on the age at onset of psychotic disorders in an Australian cohort.
    Stefanis NC; Dragovic M; Power BD; Jablensky A; Castle D; Morgan VA
    Schizophr Res; 2014 Jul; 156(2-3):211-6. PubMed ID: 24831390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabis-associated psychosis: Neural substrate and clinical impact.
    Murray RM; Englund A; Abi-Dargham A; Lewis DA; Di Forti M; Davies C; Sherif M; McGuire P; D'Souza DC
    Neuropharmacology; 2017 Sep; 124():89-104. PubMed ID: 28634109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Behavioral, cognitive and psychophysiological effects of cannabinoids: relevance to psychosis and schizophrenia].
    Sewell RA; Skosnik PD; Garcia-Sosa I; Ranganathan M; D'Souza DC
    Braz J Psychiatry; 2010 May; 32 Suppl 1():S15-30. PubMed ID: 20512267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial predisposition for psychiatric disorder: comparison of subjects treated for cannabis-induced psychosis and schizophrenia.
    Arendt M; Mortensen PB; Rosenberg R; Pedersen CB; Waltoft BL
    Arch Gen Psychiatry; 2008 Nov; 65(11):1269-74. PubMed ID: 18981338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medicinal cannabis (Bedrolite) substitution therapy in inpatients with a psychotic disorder and a comorbid cannabis use disorder: A case series.
    Schipper R; Dekker M; de Haan L; van den Brink W
    J Psychopharmacol; 2018 Mar; 32(3):353-356. PubMed ID: 29039260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabis use and psychosis: a review of reviews.
    Hasan A; von Keller R; Friemel CM; Hall W; Schneider M; Koethe D; Leweke FM; Strube W; Hoch E
    Eur Arch Psychiatry Clin Neurosci; 2020 Jun; 270(4):403-412. PubMed ID: 31563981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical use of cannabis. Cannabidiol: a new light for schizophrenia?
    Deiana S
    Drug Test Anal; 2013 Jan; 5(1):46-51. PubMed ID: 23109356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabinoids and psychosis.
    D'Souza DC
    Int Rev Neurobiol; 2007; 78():289-326. PubMed ID: 17349865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabinoids and Psychosis.
    D'Souza DC; Radhakrishnan R; Sherif M; Cortes-Briones J; Cahill J; Gupta S; Skosnik PD; Ranganathan M
    Curr Pharm Des; 2016; 22(42):6380-6391. PubMed ID: 27568729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review.
    Sarris J; Sinclair J; Karamacoska D; Davidson M; Firth J
    BMC Psychiatry; 2020 Jan; 20(1):24. PubMed ID: 31948424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.